Treatment of sarcopenia: the road to the future
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
This year, two new consensus conferences on the diagnosis and management of sarcopenia have been published.1, 2 Both confirm the need to screen for sarcopenia in older persons. Suggested screening approaches are the SARC-F,3, 4 the Ishii screening test,5, 6 or grip strength. It should be recognized that grip strength was suggested for screening by one consensus group1 and as part of the diagnosis by the other.2 Measuring mid-calf muscle circumference improves the sensitivity and specificity of the SARC-F when it is compared with the consensus definitions.7-9 A number of consensus definitions for sarcopenia have been developed.2, 11-13 All require either functional impairment (slow walking speed) or grip strength together with a low muscle mass. While the persons diagnosed by any of these definitions overlap, they all have different sensitivity and specificity when compared with one another or functional outcomes due to the different cut-off points.14, 15 The Asian Group made it clear that cut-offs are very different for persons with Asian ethnicity compared with Europeans.13 [These definitions have led to the International Classification of Disease (10th edition) to recognize sarcopenia as an independent condition (M62.84)].16, 17 There are a number of different methods available to measure lean body mass including air displacement plethysmography, bioelectrical impedance analyses, dual-energy X-ray absorptiometry, and ultrasound.18-21 Each of these methods has been demonstrated to have problems in accurately determining muscle mass.22 Recently, D3-creatine dilution has been demonstrated to be more accurate in measuring muscle mass23 and more strongly related to physical performance.22 While age-related sarcopenia is considered to be primary sarcopenia, a number of disease states, for example, diabetes mellitus,24, 25 male hypogonadism,26, 27 and chronic obstructive pulmonary disease28 can produce secondary sarcopenia. Cachexia is a complex metabolism disorder leading to anorexia, muscle wasting, and loss of fat.29 The Glasgow Prognostic Score (low serum albumin and elevated C-reactive protein) can be used to distinguish secondary sarcopenia from cachexia.30 The advent of patient-centred (P4) care has increased attention to the fact that different molecular changes can result in the need to have different therapeutic approaches to similar conditions such as sarcopenia31, 32 (Table 1). In this issue of the journal, Riuzzi et al.33 highlight that sarcopenia can result from a variety of molecular changes resulting in changes in myofibre metabolism and alterations in satellite cell properties. Abnormalities in these pathways can be due to insulin growth factor-1/insulin receptors, activin (myostatin) receptors, tropomysin receptor, kinase C receptors (neurotrophin and G-protein receptors), a variety of cytokines, and testosterone through activation of β-catenin.34-38 Thus, in the long run, the ideal treatment of sarcopenia will involve identification of the aberrant molecular pathway and the possible hormone causing this imbalance. At present, the treatment of sarcopenia is focused on resistance exercise.1 The use of leucine essential amino acids and/or β-hydroxybutyrate has not been clearly established but would seem a reasonable adjunct in persons with low protein intake.39-45 Drugs that have potential to treat sarcopenia include testosterone and anabolic steroids,46-48 myostatin antibodies,49, 50 activin receptor antibodies,51 and the ghrelin agonist, anamorelin.52 There is also interest in the role of beta-blockade,53 some angiotensin-converting enzyme inhibitors,54 and sarconeos, which activates the MAS (angiotensin-1) receptor.55 A recent study suggested that metformin may improve mobility in persons with diabetes mellitus.56 Still highly experimental but likely to play a role in the future management of sarcopenia are CRISPR techniques57 and possibly stem cell therapy.58 Sarcopenia is a major cause of physical frailty59-61 and falls62, 63 in older persons. As at present, there is a simple therapy—aggressive resistance exercise—when sarcopenia is detected early, it seems reasonable to screen older persons and those with diabetes for sarcopenia and frailty using the Rapid Geriatric Assessment tool64-67 and begin secondary prevention as early as possible. The SarQOL can be utilized to measure an improvement of health-related quality of life in these persons.68 A recent study demonstrated that an intense level of physical exercise in hospital patients can prevent the muscle and functional loss that occurs in hospitalized patients.69 The author certifies that he complies with the ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2017.70 None declared.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Sarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Chen, L.-K., Liu, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Bahyah, K. S., Chou, M.-Y., Chen, L.-Y., Hsu, P.-S., Krairit, O., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.11.025 · Cited by 4,051 · cited 2×
“While the persons diagnosed by any of these definitions overlap, they all have different sensitivity and specificity when compared with one another or functional outcomes due to the different cut-off points.14,15 The Asian Group made it clear that cut-offs are very different for persons with Asian ethnicity compared w…”
BackgroundSarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Fielding, R. A., Vellas, B., Evans, W. J., Bhasin, S., Morley, J. E., Newman, A. B., Abellan van Kan, G., Andrieu, S., Bauer, J., Breuille, D., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.01.003 · Cited by 3,256
Self-citationBauer, J., Biolo, G., Cederholm, T., Cesari, M., Cruz-Jentoft, A. J., Morley, J. E., Phillips, S., Sieber, C., Stehle, P., Teta, D., et al. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.05.021 · Cited by 2,553
Self-citationSARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes
Malmstrom, T. K., Miller, D. K., Simonsick, E. M., Ferrucci, L., & Morley, J. E. (2016) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12048 · Cited by 1,155
Self-citationDent, E., Morley, J. E., Cruz-Jentoft, A. J., Arai, H., Kritchevsky, S. B., Guralnik, J., Bauer, J. M., Pahor, M., Clark, B. C., Cesari, M., et al. (2018) · The Journal of nutrition, health and aging · doi:10.1007/s12603-018-1139-9 · Cited by 1,130 · cited 2×
“This year, two new consensus conferences on the diagnosis and management of sarcopenia have been published.(1,2) Both”
BackgroundSelf-citationWelcome to the ICD‐10 code for sarcopenia
Anker, S. D., Morley, J. E., & von Haehling, S. (2016) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12147 · Cited by 983
Self-citationBauer, J. M., Verlaan, S., Bautmans, I., Brandt, K., Donini, L. M., Maggio, M., McMurdo, M. E. T., Mets, T., Seal, C., Wijers, S. L., et al. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.05.021 · Cited by 670
Martínez-Velilla, N., Casas-Herrero, A., Zambom-Ferraresi, F., Sáez de Asteasu, M. L., Lucia, A., Galbete, A., García-Baztán, A., Alonso-Renedo, J., González-Glaría, B., Gonzalo-Lázaro, M., et al. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.4869 · Cited by 481 · cited 1×
“physical exercise in hospital patients can prevent the muscle and functional loss that occurs in hospitalized patients.(69) Acknowledgement”
Background
Cited by
Xia, L., Zhao, R., Wan, Q., Wu, Y., Zhou, Y., Wang, Y., Cui, Y., Shen, X., & Wu, X. (2020) · Cancer Medicine · doi:10.1002/cam4.3428 · Cited by 321
Rooks, D., Swan, T., Goswami, B., Filosa, L. A., Bunte, O., Panchaud, N., Coleman, L. A., Miller, R. R., Garcia Garayoa, E., Praestgaard, J., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.20836 · Cited by 177
Shin, M. J., Jeon, Y. K., & Kim, I. J. (2018) · The World Journal of Men's Health · doi:10.5534/wjmh.180001 · Cited by 134
Liang, Y., Wang, R., Jiang, J., Tan, L., & Yang, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-75872-2 · Cited by 42
Metadata
- Authors
- Morley, J. E.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2018-12
- Volume
- 9
- Issue
- 7
- Pages
- 1196-1199
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W2912282082
- Cited by
- 70
- References
- 25
- FWCI
- 6.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of sarcopenia: the road to the future. https://app.cochat.ai/papers/10.1002/jcsm.12386
- The paper
- Morley, J. E. (2018). Treatment of sarcopenia: the road to the future. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.12386
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.